MDT

98.85

+0.46%↑

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

MDT

98.85

+0.46%↑

145.27

-1.04%↓

VEEV

219.02

+0.28%↑

HQY

87.05

+2.06%↑

NEOG

9.56

+1.59%↑

Inicio・Lista de Acciones・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Abierto

SectorSalud

36.08 3.41

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

35.09

Máximo

36.65

Métricas clave
By Trading Economics
Ingresos	11M 51M
Ventas	39M 239M
P/B Media del Sector	12.073 90.831
BPA	1.08
Margen de beneficio	21.242
Empleados	268
EBITDA	14M 73M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+22.34% upside

Dividendos
By Dow Jones
Próximas Ganancias	24 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	517M 2.2B
Apertura anterior	32.67
Cierre anterior	36.08

Noticias sobre sentimiento de mercado

By Acuity

50%

151 / 361 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

29.8 / N/A Soporte y Resistencia

Harmony Biosciences Holdings Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ene 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 ene 2026, 00:00 UTC

Ganancias

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 ene 2026, 23:47 UTC

Charlas de Mercado

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 ene 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 ene 2026, 23:39 UTC

Charlas de Mercado

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 ene 2026, 23:32 UTC

Charlas de Mercado

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 ene 2026, 22:56 UTC

Adquisiciones, fusiones, absorciones

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 ene 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 ene 2026, 22:17 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 ene 2026, 22:17 UTC

Charlas de Mercado

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 ene 2026, 22:09 UTC

Ganancias

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 ene 2026, 22:08 UTC

Ganancias

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 ene 2026, 22:08 UTC

Ganancias

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 ene 2026, 21:53 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 ene 2026, 21:53 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 ene 2026, 21:52 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Announces Positive Profit Alert for 2025

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

Citigroup Acting as Financial Advisor to WuXi XDC

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 ene 2026, 21:50 UTC

Charlas de Mercado

Ganancias

Financial Services Roundup: Market Talk

14 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

14 ene 2026, 21:49 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 ene 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 ene 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Makes Cash Offer for BioDlink International

14 ene 2026, 21:13 UTC

Charlas de Mercado

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 ene 2026, 20:30 UTC

Charlas de Mercado

Ganancias

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 ene 2026, 20:13 UTC

Charlas de Mercado

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 ene 2026, 20:08 UTC

Charlas de Mercado

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 ene 2026, 19:33 UTC

Charlas de Mercado

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 ene 2026, 19:06 UTC

Charlas de Mercado

Ganancias

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Comparación entre iguales

Cambio de precio

Harmony Biosciences Holdings Inc Esperado

Precio Objetivo

By TipRanks

22.34% repunte

Estimación a 12 meses

Media 43.75 USD 22.34%

Máximo 55 USD

Mínimo 32 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Harmony Biosciences Holdings Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Harmony Biosciences Holdings Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

29.8 / N/ASoporte y Resistencia

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

151 / 361 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.